Perspectives in Lung Cancer Care Virtual Meeting

August 6th, 2021: 10:30 – 11:30am PT, 1:30 – 2:30pm ET

Join Drs. Edgardo Santos, Snehal Thakkar, and Kristin Gunderson at PLCC 2021 for a symposium entitled: “What Can We Learn from NSCLC? Using Comprehensive Genomic Profiling to Enhance Patient Care”.

New Cut Point for Unfavorable Intermediate and High-Risk Patients

Oncotype DX Genomic Prostate Score

The Oncotype DX GPS assay stratifies unfavorable intermediate and high-risk patients into two distinct groups with highly differing long-term outcomes.

Medicare Coverage Update

Oncotype DX Genomic Prostate Score

The Oncotype DX Genomic Prostate Score Assay is now covered by Medicare for all intermediate-risk prostate cancer patients.

Western Section of the AUA

Available On-Demand

Join speaker Dr. Rob Reiter for the virtual WAUA symposium on "Commercial Genomic Assays for Localized Prostate Cancer: How Do They Compare?"

20-Year Outcomes

Oncotype DX Genomic Prostate Score

New follow-up data suggests that the GPS result may be associated with prostate cancer outcomes for up to 20 years after diagnosis.
Making cancer care smarter.™

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.